{"id":"NCT05369403","sponsor":"Eli Lilly and Company","briefTitle":"A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab","officialTitle":"An Open-Label, Study to Evaluate the Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-12-19","primaryCompletion":"2024-01-11","completion":"2025-02-05","firstPosted":"2022-05-11","resultsPosted":"2025-03-19","lastUpdate":"2025-03-19"},"enrollment":86,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Atopic Dermatitis"],"interventions":[{"type":"DRUG","name":"Lebrikizumab","otherNames":["LY3650150","DRM06"]}],"arms":[{"label":"Lebrikizumab","type":"EXPERIMENTAL"}],"summary":"The study will assess the safety and efficacy of lebrikizumab in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD) previously treated with Dupilumab.","primaryOutcome":{"measure":"Percentage of Participants Achieving Eczema Area and Severity Index 75 (EASI75) at Week 16","timeFrame":"Week 16","effectByArm":[{"arm":"Lebrikizumab 250mg Q2W","deltaMin":57.4,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":10},"locations":{"siteCount":37,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":["https://trials.lilly.com/en-US/trial/343315"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":86},"commonTop":["Dermatitis atopic","Upper respiratory tract infection","Injection site pain","Conjunctivitis","Nasopharyngitis"]}}